Videos

Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.

Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.

Angela Hirbe, MD, PhD, discusses long-term follow-up results from the phase 2b ReNeu trial evaluating mirdametinib among adult and pediatric patients with inoperable, symptomatic NF1-associated plexiform neurofibromas.

Binod Dhakal, MD, discusses results from the CARTITUDE-4 trial evaluating the impact of bridging therapy response in relapsed multiple myeloma refractory to lenalidomide.

Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.

Luciano Costa, MD, discusses long-term results from the CARTITUDE-4 trial evaluating ciltacabtagene autoleucel in patients with of standard-risk relapsed/refractory multiple myeloma.

Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.

At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.

At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.

Donald Moore, PharmD, discusses results from a multicenter retrospective analysis comparing dexamethasone and tocilizumab for management of CRS in patients receiving talquetamab for relapsed/refractory multiple myeloma.